ISMMS, Boehringer Ingelheim to test nintedanib for treating pulmonary fibrosis post-COVID-19 infection Read more
Bridge Biotherapeutics, Boehringer Ingelheim cancel agreement to develop BBT-877 for idiopathic pulmonary fibrosis Read more
Drug makers, BMGF pledge to strive for global access to COVID-19 diagnostics, therapeutics and vaccines Read more
SGLT-2 inhibitors may primarily drive growth of branded heart failure treatment market: GlobalData Read more
Boehringer Ingelheim and Click Therapeutics join hands for CT-155, digital therapeutic for schizophrenia Read more
Empagliflozin reduced risk of death and hospitalisation for heart failure by 25 per cent in adults Read more
CARE consortium launched to fast-track discovery and development of medicines to treat COVID-19 Read more